SCHEMBL16332162

SCHEMBL16332162

Cn1c(-c2ccsc2)cc2c(Nc3cccnc3)nccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FYN P06241 4/20 0.42
▸ CYP3A4 P08684 3/20 0.40
▸ CYP2C9 P11712 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ CYP2A6 P11509 1/20 0.40
▸ CYP2B6 P20813 1/20 0.40
▸ CD38 P28907 1/20 0.39
▸ MAP4K4 O95819 1/20 0.37
▸ GSK3B P49841 1/20 0.37
▸ CYP1A2 P05177 2/20 0.35
▸ KDM1A O60341 1/20 0.35
▸ RCOR1 Q9UKL0 1/20 0.35
▸ PDE5A O76074 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ RAF1 P04049 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HIF1A Q16665 1/20 0.35
▸ CCNA2 P20248 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ CCNA1 P78396 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16332075 0.88 FYN (0.40) FYNCYP3A4CYP2C9CYP2C19CD38
SCHEMBL16373693 0.86 FYN (0.46) FYNCYP3A4CYP2C9CYP2C19CYP1A2
SCHEMBL16373491 0.86 FYN (0.46) FYNCYP3A4CYP2C9CYP2C19CD38
SCHEMBL16332052 0.83 FYN (0.39) FYNCYP3A4CYP2C9CYP2C19CYP1A2
SCHEMBL16332660 0.83 FYN (0.44) FYNCYP3A4CYP2C9CYP2C19MAP4K4
SCHEMBL16331528 0.83 CYP2A6 (0.44) FYNCYP2A6LMNA
SCHEMBL16331336 0.82 FYN (0.42) FYNCD38MAP4K4GSK3BCDK5
SCHEMBL16332258 0.82 FYN (0.51) FYNCYP3A4CYP2C9CYP2C19CYP1A2
SCHEMBL16331623 0.82 FYN (0.51) FYNRAF1MAPK1CCNA2CDK2
SCHEMBL16332149 0.82 FYN (0.42) FYNLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458463-B2 Method for treatment of diabetes by a small molecule inhibitor for GRK5 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2016-10-04 — — US claimed
EP-2818472-A1 Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2014-12-31 — — EP claimed
US-9458463-B2 Method for treatment of diabetes by a small molecule inhibitor for GRK5 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2016-10-04 — — US disclosed
US-20150079108-A1 KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-03-19 — — US disclosed
EP-2818472-A1 Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2014-12-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150079108-A1 KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY GCKR, GRK4, GRK5 FYN 574/4885CYP3A4 4480/4885CYP2C9 4811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback